CLINICAL TRIALS PROFILE FOR ATOGEPANT
✉ Email this page to a colleague
All Clinical Trials for atogepant
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02848326 ↗ | Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention | Completed | Allergan | Phase 2/Phase 3 | 2016-09-06 | This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship. |
NCT03700320 ↗ | Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine | Completed | Allergan | Phase 3 | 2018-10-08 | This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year. |
NCT03777059 ↗ | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | Completed | Allergan | Phase 3 | 2018-12-14 | To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine. |
NCT03855137 ↗ | Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine | Active, not recruiting | Allergan | Phase 3 | 2019-03-11 | This study will evaluate the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study includes a 12-week treatment period. |
NCT03939312 ↗ | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | Completed | Allergan | Phase 3 | 2019-05-06 | To evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine. |
NCT04437433 ↗ | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine | Enrolling by invitation | Allergan | Phase 3 | 2020-06-18 | This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Japanese Participants with Chronic or Episodic Migraine |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for atogepant
Condition Name
Clinical Trial Locations for atogepant
Trials by Country
Clinical Trial Progress for atogepant
Clinical Trial Phase
Clinical Trial Sponsors for atogepant
Sponsor Name